325
Views
5
CrossRef citations to date
0
Altmetric
Review

Review of Treatment Options for Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation

, , , , &
Pages 1457-1468 | Published online: 21 Apr 2021

References

  • Lacy BE, Mearin F, Chang L, et al. Bowel disorders. Gastroenterology. 2016;150(6):1393–1407.e5. doi:10.1053/j.gastro.2016.02.031
  • Heidelbaugh JJ, Stelwagon M, Miller SA, Shea EP, Chey WD. The spectrum of constipation-predominant irritable bowel syndrome and chronic idiopathic constipation: US survey assessing symptoms, care seeking, and disease burden. Am J Gastroenterol. 2015;110(4):580–587. doi:10.1038/ajg.2015.67
  • Drossman DA. Functional gastrointestinal disorders: history, pathophysiology, clinical features, and Rome IV. Gastroenterology. 2016;150(6):1262–1279. doi:10.1053/j.gastro.2016.02.032
  • Halder SLS, Locke GR, Schleck CD, Zinsmeister AR, Melton LJ, Talley NJ. Natural history of functional gastrointestinal disorders: a 12-year longitudinal population-based study. Gastroenterology. 2007;133(3):799–807. doi:10.1053/j.gastro.2007.06.010
  • Harris LA, Horn J, Kissous-Hunt M, Magnus L, Quigley EMM. The better understanding and recognition of the disconnects, experiences, and needs of patients with chronic idiopathic constipation (BURDEN-CIC) study: results of an online questionnaire. Adv Ther. 2017;34(12):2661–2673. doi:10.1007/s12325-017-0633-5
  • Lacy BE, Moreau JC. Diarrhea-predominant irritable bowel syndrome: diagnosis, etiology, and new treatment considerations. J Am Assoc Nurse Pract. 2016;28(7):393–404. doi:10.1002/2327-6924.12387
  • Vazquez Roque M, Bouras EP. Epidemiology and management of chronic constipation in elderly patients. Clin Interv Aging. 2015;10:919–930. doi:10.2147/CIA.S54304
  • Higgins PDR, Johanson JF. Epidemiology of constipation in North America: a systematic review. Am J Gastroenterol. 2004;99(4):750–759. doi:10.1111/j.1572-0241.2004.04114.x
  • Bouras EP, Tangalos EG. Chronic constipation in the elderly. Gastroenterol Clin North Am. 2009;38(3):463–480. doi:10.1016/j.gtc.2009.06.001
  • Doshi JA, Cai Q, Buono JL, et al. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population. J Manag Care Pharm. 2014;20(4):382–390. doi:10.18553/jmcp.2014.20.4.382
  • Saito YA, Schoenfeld P, Locke GR. The epidemiology of irritable bowel syndrome in North America: a systematic review. Am J Gastroenterol. 2002;97(8):1910–1915. doi:10.1111/j.1572-0241.2002.05913.x
  • Hungin APS, Chang L, Locke GR, Dennis EH, Barghout V. Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact. Aliment Pharmacol Ther. 2005;21(11):1365–1375. doi:10.1111/j.1365-2036.2005.02463.x
  • Choung RS, Locke GR, Schleck CD, Zinsmeister AR, Talley NJ. Cumulative incidence of chronic constipation: a population-based study 1988–2003. Aliment Pharmacol Ther. 2007;26(11–12):1521–1528. doi:10.1111/j.1365-2036.2007.03540.x
  • Canavan C, West J, Card T. The epidemiology of irritable bowel syndrome. Clin Epidemiol. 2014;6:71–80. doi:10.2147/CLEP.S40245
  • Houghton LA, Heitkemper M, Crowell MD, et al. Age, gender, and women’s health and the patient. Gastroenterology. 2016;150(6):1332–1343.e4. doi:10.1053/j.gastro.2016.02.017
  • Nellesen D, Yee K, Chawla A, Lewis BE, Carson RT. A systematic review of the economic and humanistic burden of illness in irritable bowel syndrome and chronic constipation. J Manag Care Pharm. 2013;19(9):755–764. doi:10.18553/jmcp.2013.19.9.755
  • Ruiz-López MC, Coss-Adame E. Quality of life in patients with different constipation subtypes based on the Rome III criteria. Rev Gastroenterol Mex. 2015;80(1):13–20. doi:10.1016/j.rgmx.2015.01.003
  • Johanson JF, Kralstein J. Chronic constipation: a survey of the patient perspective. Aliment Pharmacol Ther. 2007;25(5):599–608. doi:10.1111/j.1365-2036.2006.03238.x
  • American Gastroenterological Association. IBS in America: survey summary findings. 2015. Available from: http://www.multivu.com/players/English/7634451-aga-ibs-in-america-survey/docs/survey-findings-pdf-635473172.pdf. Accessed August 24, 2020.
  • Chey WD, Kurlander J, Eswaran S. Irritable bowel syndrome: a clinical review. JAMA. 2015;313(9):949–958. doi:10.1001/jama.2015.0954
  • Platt FW, Gaspar DL, Coulehan JL, et al. “Tell me about yourself”: the patient-centered interview. Ann Intern Med. 2001;134(11):1079–1085. doi:10.7326/0003-4819-134-11-200106050-00020
  • Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol. 1997;32(9):920–924. doi:10.3109/00365529709011203
  • Patel S, DeSimone E, Doerfler BM, Halpert A, Lucak S. Irritable bowel syndrome: practical considerations for nurse practitioners and physician assistants. 2018. Available from: https://www.consultant360.com/article/gastroenterology/irritable-bowel-syndrome/irritable-bowel-syndrome-practical-considerations. Accessed January 21, 2019.
  • Mearin F, Ciriza C, Mínguez M, et al. Clinical practice guideline: irritable bowel syndrome with constipation and functional constipation in the adult. Rev Esp Enferm Dig. 2016;108(6):332–363. doi:10.17235/reed.2016.4389/2016
  • Mounsey A, Raleigh M, Wilson A. Management of constipation in older adults. Am Fam Physician. 2015;92(6):500–504.
  • Ford AC, Moayyedi P, Chey WD, et al. American College of Gastroenterology monograph on management of irritable bowel syndrome. Am J Gastroenterol. 2018;113(Suppl 2):1–18. doi:10.1038/s41395-018-0084-x
  • Ford AC, Moayyedi P, Lacy BE, et al. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol. 2014;109(Suppl 1):S2–S26. doi:10.1038/ajg.2014.187
  • Rao SSC, Yu S, Fedewa A. Systematic review: dietary fibre and FODMAP-restricted diet in the management of constipation and irritable bowel syndrome. Aliment Pharmacol Ther. 2015;41(12):1256–1270. doi:10.1111/apt.13167
  • Chey WD, Keefer L, Whelan K, Gibson PR. Behavioral and diet therapies in integrated care for patients with irritable bowel syndrome. Gastroenterology. 2021;160(1):47–62. doi:10.1053/j.gastro.2020.06.099
  • McRorie JW Jr, Fahey GC Jr, Gibb RD, Chey WD. Laxative effects of wheat bran and psyllium: resolving enduring misconceptions about fiber in treatment guidelines for chronic idiopathic constipation. J Am Assoc Nurse Pract. 2020;32(1):15–23. doi:10.1097/JXX.0000000000000346
  • Lever E, Cole J, Scott SM, Emery PW, Whelan K. Systematic review: the effect of prunes on gastrointestinal function. Aliment Pharmacol Ther. 2014;40(7):750–758. doi:10.1111/apt.12913
  • Chapman RW, Stanghellini V, Geraint M, Halphen M. Randomized clinical trial: macrogol/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome. Am J Gastroenterol. 2013;108(9):1508–1515. doi:10.1038/ajg.2013.197
  • Kamm MA, Mueller-Lissner S, Wald A, Richter E, Swallow R, Gessner U. Oral bisacodyl is effective and well-tolerated in patients with chronic constipation. Clin Gastroenterol Hepatol. 2011;9(7):577–583. doi:10.1016/j.cgh.2011.03.026
  • Chang FY. Irritable bowel syndrome: the evolution of multi-dimensional looking and multidisciplinary treatments. World J Gastroenterol. 2014;20(10):2499–2514. doi:10.3748/wjg.v20.i10.2499
  • Nag A, Martin SA, Mladsi D, Olayinka-Amao O, Purser M, Vekaria RM. The humanistic and economic burden of chronic idiopathic constipation in the USA: a systematic literature review. Clin Exp Gastroenterol. 2020;13:255–265. doi:10.2147/CEG.S239205
  • Peckham EJ, Cooper K, Roberts ER, Agrawal A, Brabyn S, Tew G. Homeopathy for treatment of irritable bowel syndrome. Cochrane Database Syst Rev. 2019;9(9):CD009710. doi:10.1002/14651858.CD009710.pub3
  • Lucak S, Chang L, Halpert A, Harris LA. Current and emergent pharmacologic treatments for irritable bowel syndrome with diarrhea: evidence-based treatment in practice. Therap Adv Gastroenterol. 2017;10(2):253–275. doi:10.1177/1756283X16663396
  • Chey WD. Symposium report: an evidence-based approach to IBS and CIC: applying new advances to daily practice: a review of an adjunct clinical symposium of the American College of Gastroenterology Meeting October 16, 2016, Las Vegas, Nevada. Gastroenterol Hepatol (N.Y.) 2017;13(2 suppl 1):1–16.
  • DiPalma JA, Cleveland MV, McGowan J, Herrera JL. A randomized, multicenter, placebo-controlled trial of polyethylene glycol laxative for chronic treatment of chronic constipation. Am J Gastroenterol. 2007;102(7):1436–1441. doi:10.1111/j.1572-0241.2007.01199.x
  • US Food and Drug Administration. Linzess – highlights of prescribing information. 2020. Available from: https://media.allergan.com/actavis/actavis/media/allergan-pdf-documents/product-prescribing/Final_labeling_text_10-2018-AR-updates-LINZESS-clean.pdf. Accessed February, 2021.
  • Rao S, Lembo AJ, Shiff SJ, et al. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol. 2012;107(11):1714–1724. doi:10.1038/ajg.2012.255
  • Chey WD, Lembo AJ, Lavins BJ, et al. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol. 2012;107(11):1702–1712. doi:10.1038/ajg.2012.254
  • Lembo AJ, Schneier HA, Shiff SJ, et al. Two randomized trials of linaclotide for chronic constipation. N Engl J Med. 2011;365(6):527–536. doi:10.1056/NEJMoa1010863
  • US Food and Drug Administration. Amitiza – highlights of prescribing information. 2020. Available from: https://general.takedapharm.com/amitizapi. Accessed February 26, 2021.
  • Drossman DA, Chey WD, Johanson JF, et al. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome – results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther. 2009;29(3):329–341. doi:10.1111/j.1365-2036.2008.03881.x
  • US Food and Drug Administration. Trulance – highlights of prescribing information. 2018. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208745s001lbl.pdf. Accessed August, 2020.
  • Brenner DM, Fogel R, Dorn SD, et al. Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials. Am J Gastroenterol. 2018;113(5):735–745. doi:10.1038/s41395-018-0026-7
  • DeMicco M, Barrow L, Hickey B, Shailubhai K, Griffin P. Randomized clinical trial: efficacy and safety of plecanatide in the treatment of chronic idiopathic constipation. Therap Adv Gastroenterol. 2017;10(11):837–851. doi:10.1177/1756283X17734697
  • Miner PB Jr, Koltun WD, Wiener GJ, et al. A randomized Phase III clinical trial of plecanatide, a uroguanylin analog, in patients with chronic idiopathic constipation. Am J Gastroenterol. 2017;112(4):613–621. doi:10.1038/ajg.2016.611
  • US Food and Drug Administration. Prucalopride – highlights of prescribing information. 2018. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210166s000lbl.pdf. Accessed July 26, 2019.
  • Camilleri M, Kerstens R, Rykx A, Vandeplassche L. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med. 2008;358(22):2344–2354. doi:10.1056/NEJMoa0800670
  • Quigley EMM, Vandeplassche L, Kerstens R, Ausma J. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation – a 12-week, randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2009;29(3):315–328. doi:10.1111/j.1365-2036.2008.03884.x
  • US Food and Drug Administration. Zelnorm – highlights of prescribing information. 2019. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021200Orig1s015lbl.pdf. Accessed April 22, 2019.
  • US Food and Drug Administration. IBSRELA – highlights of prescribing information. 2019. Available from: https://ardelyx.com/wp-content/uploads/2019/09/PI-Approval.pdf. Accessed December 13, 2019.
  • Ford AC, Talley NJ, Schoenfeld PS, Quigley EMM, Moayyedi P. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut. 2009;58(3):367–378. doi:10.1136/gut.2008.163162
  • Drossman DA. Rome IV Functional Gastrointestinal Disorders, Disorders of the Gut-Brain Interaction - Volume II. 4th ed. In: Chang L, Chey WD, Kellow J, Tack J, William E. Whitehead WE, Rome IV Committees, Eds. The Rome Foundation; 2016.